Ver­tex is pulling back on its ge­net­ic med­i­cine re­search, end­ing all work re­lat­ed to ade­no-as­so­ci­at­ed virus­es, ...

SalioGen Therapeutics, led by Ray Tabibiazar, shut down after failing to perfect its bat-derived gene editing technology.

Kura gets $45M from Kyowa Kirin; Pliant cuts 45% staff; AstraZeneca's Breztri succeeds in asthma trials; Otsuka ends ...

FDA delays Cytokinetics' aficamten PDUFA date to Dec 26 after company adds REMS to heart disease drug application; stock down ...

Welcome back to Endpoints Weekly, our roundup of the top headlines in biopharma. Earnings season continued this week, with more comments from pharma executives on the potential impact of tariffs ...

Aera Therapeutics shifts focus to lipid nanoparticles for T-cell targeting therapy while continuing work on protein ...

HHS rolled out a new $500 million initiative to develop universal vaccines for 'pandemic-prone' viruses such as influenza and ...

Biogen reports Leqembi Alzheimer's drug sales reached $96M in Q1, up from $19M last year, with $52M from US market. Eisai ...

Regeneron can’t dodge a lawsuit alleging it unlawfully inflated Medicare reimbursements for its eye drug Eylea and defrauded ...

HHS Secretary Robert F. Kennedy Jr. said Friday that 35 states had signed up to participate in a new payment model meant to ...

The White House’s budget request proposes a nearly $18 billion cut to NIH spending, and nearly $4 billion slashed at the CDC. And the changes would include major consolidation at both agencies.

Amicus pays Dimerix $30M upfront for US rights to DMX-200, a late-stage FSGS therapy, with potential milestone payments of ...